Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for shares of Allogene ...

Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for LENZ Therapeutics in a note issued to investors ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

Fintel reports that on March 21, 2025, HC Wainwright & Co. downgraded their outlook for OptiNose (NasdaqGS:OPTN) from Buy to ...

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherapeutics (BRNS – Research Report) today and set a price target of ...

About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high ...

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Fintel reports that on March 17, 2025, HC Wainwright & Co. initiated coverage of Actuate Therapeutics (NasdaqGM:ACTU) with a ...

On Friday, H.C. Wainwright reaffirmed a Neutral stock rating for Adicet Bio Inc. (NASDAQ:ACET), a biotechnology company focused on the development of therapies for cancer and other diseases.

Fireside chat Damian Marron, interim CEO, will participate in a fireside chat moderated by Joe Pantginis, Managing Director, Equity Research at H.C. Wainwright & Co., LLC. March 27 at 08.00am EST ...